Press Releases

Date Title and Summary Additional Formats
Toggle Summary Evoke Pharma Appoints Vickie Reed to Board of Directors
SOLANA BEACH, Calif. , May 14, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced the appointment of Vickie Reed to the Company’s board of directors.
View HTML
Toggle Summary Evoke Pharma Reports First Quarter 2021 Financial Results
Nearly 293% growth of product sales, 235% growth of prescriptions and 87% increase in new prescribers for Gimoti ® New notice of allowance from USPTO to expand Gimoti patent estate SOLANA BEACH, Calif. , May 12, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc.
View HTML
Toggle Summary Evoke Pharma to Report First Quarter 2021 Financial Results on May 12, 2021
SOLANA BEACH, Calif. , May 05, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its first quarter 2021 financial results on
View HTML
Toggle Summary Evoke Pharma Receives Notice of Allowance from United States Patent and Trademark Office for a Method of Use Patent with Claims Covering Gimoti®
New patent expands intellectual property protection for nasal delivery of metoclopramide SOLANA BEACH, Calif. , April 06, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that the
View HTML
Toggle Summary Evoke Pharma Announces a Fireside Chat with Key Opinion Leaders on the Treatment of Gastroparesis
SOLANA BEACH, Calif. , March 30, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a commercial stage specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that Yale Jen, Senior Biotech Analyst at Laidlaw & Company will
View HTML
Toggle Summary Evoke Pharma Reports Fourth Quarter and Full Year 2020 Financial Results
Encouraging early traction from GIMOTI™ commercial launch SOLANA BEACH, Calif. , March 11, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases, today announced its financial results for the
View HTML
Toggle Summary Evoke Pharma to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
SOLANA BEACH, Calif. , March 04, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that the Company is scheduled to release its fourth quarter and full year 2020
View HTML
Toggle Summary Evoke Pharma Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares
SOLANA BEACH, Calif. , Jan. 20, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, announced today the completion of its follow-on offering of 5,750,000 shares of its common stock,
View HTML
Toggle Summary Evoke Pharma Announces Pricing of Public Offering of Common Stock
SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it has priced an underwritten public offering of 5,000,000 shares of its common
View HTML
Toggle Summary Evoke Pharma Announces Proposed Public Offering of Common Stock
SOLANA BEACH, Calif. , Jan. 13, 2021 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (Nasdaq: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) disorders and diseases, today announced that it intends to offer and sell shares of its common stock in a “firm commitment”
View HTML